Immunome, Inc. (IMNM)
24.15
+0.69
(+2.94%)
USD |
NASDAQ |
Sep 17, 12:11
Immunome Shareholders Equity (Quarterly) : 525.08M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 525.08M |
| March 31, 2026 | 588.69M |
| December 31, 2025 | 634.34M |
| September 30, 2025 | 263.92M |
| June 30, 2025 | 269.27M |
| March 31, 2025 | 307.13M |
| December 31, 2024 | 181.16M |
| September 30, 2024 | 214.91M |
| June 30, 2024 | 253.84M |
| March 31, 2024 | 285.57M |
| December 31, 2023 | 119.88M |
| September 30, 2023 | 6.076M |
| Date | Value |
|---|---|
| June 30, 2023 | 9.338M |
| March 31, 2023 | 13.86M |
| December 31, 2022 | 16.65M |
| September 30, 2022 | 23.08M |
| June 30, 2022 | 30.28M |
| March 31, 2022 | 37.87M |
| December 31, 2021 | 48.18M |
| September 30, 2021 | 54.79M |
| June 30, 2021 | 60.62M |
| March 31, 2021 | 37.88M |
| December 31, 2020 | 41.34M |
| September 30, 2020 | -49.08M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 565.38M |
| Total Liabilities (Quarterly) | 40.30M |
| Debt to Equity Ratio | 0.009 |
| Current Ratio | 15.08 |
| Net Debt Paydown Yield | 0.00% |